BRPI0814140A2 - composição de peptídeos associados a tumor e vacina anticâncer relacionada - Google Patents

composição de peptídeos associados a tumor e vacina anticâncer relacionada

Info

Publication number
BRPI0814140A2
BRPI0814140A2 BRPI0814140A BRPI0814140A BRPI0814140A2 BR PI0814140 A2 BRPI0814140 A2 BR PI0814140A2 BR PI0814140 A BRPI0814140 A BR PI0814140A BR PI0814140 A BRPI0814140 A BR PI0814140A BR PI0814140 A2 BRPI0814140 A2 BR PI0814140A2
Authority
BR
Brazil
Prior art keywords
tumor
cancer
peptide composition
associated peptide
related vaccine
Prior art date
Application number
BRPI0814140A
Other languages
English (en)
Inventor
Trautwein Claudia
Singh Harpreet
Schoor Oliver
Lewandrowski Peter
Walter Steffen
Weinschenk Toni
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Priority to BR122013005232-1A priority Critical patent/BR122013005232A2/pt
Publication of BRPI0814140A2 publication Critical patent/BRPI0814140A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46448—Cancer antigens from embryonic or fetal origin
    • A61K39/464482—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0814140A 2007-07-27 2008-07-25 composição de peptídeos associados a tumor e vacina anticâncer relacionada BRPI0814140A2 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122013005232-1A BR122013005232A2 (pt) 2007-07-27 2008-07-25 Peptídeo; ácido nucleico ou vetor de expressão; célula hospedeira; método in vitro para produzir linfócitos t citotóxicos ativados; tais linfócitos; e usos

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07014796 2007-07-27
US95310907P 2007-07-31 2007-07-31
US98124107P 2007-10-19 2007-10-19
PCT/EP2008/006152 WO2009015841A1 (en) 2007-07-27 2008-07-25 Composition of tumour-associated peptides and related anti-cancer vaccine

Publications (1)

Publication Number Publication Date
BRPI0814140A2 true BRPI0814140A2 (pt) 2017-03-28

Family

ID=39926464

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814140A BRPI0814140A2 (pt) 2007-07-27 2008-07-25 composição de peptídeos associados a tumor e vacina anticâncer relacionada

Country Status (21)

Country Link
US (1) US7994276B2 (pt)
EP (2) EP2178557B1 (pt)
JP (2) JP5352586B2 (pt)
KR (1) KR101167392B1 (pt)
CN (2) CN101765434B (pt)
AU (1) AU2008281013B2 (pt)
BR (1) BRPI0814140A2 (pt)
CA (2) CA2694771A1 (pt)
DK (1) DK2567707T3 (pt)
EA (2) EA023928B1 (pt)
ES (1) ES2608583T3 (pt)
HK (1) HK1182923A1 (pt)
HU (1) HUE032379T2 (pt)
LT (1) LT2567707T (pt)
MX (1) MX2010001088A (pt)
NZ (1) NZ582823A (pt)
PL (1) PL2567707T3 (pt)
PT (1) PT2567707T (pt)
SI (1) SI2567707T1 (pt)
UA (2) UA117216C2 (pt)
WO (1) WO2009015841A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
JP5352586B2 (ja) * 2007-07-27 2013-11-27 イマティクス バイオテクノロジーズ ゲーエムベーハー 腫瘍関連ペプチドおよび関連抗癌ワクチンの組成物
HUE024541T2 (hu) * 2008-05-14 2016-01-28 Immatics Biotechnologies Gmbh Szurvivinbõl és neurocanból származó új és hatásos II-es osztályú MHC peptidek
GB201019331D0 (en) * 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
SG10201608552WA (en) * 2011-10-28 2016-12-29 Oncotherapy Science Inc Topk Peptides And Vaccines Including The Same
EP2847322B1 (en) 2012-05-08 2019-06-26 Western University Of Health Sciences Standardized ex vivo platforms for the antigen-specific expansion of cd4+ t cell populations
GB201214007D0 (en) * 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
TWI777198B (zh) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（七）
US11203783B2 (en) 2013-11-21 2021-12-21 Repertoire Genesis Incorporation T cell receptor and B cell receptor repertoire analysis system, and use of same in treatment and diagnosis
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
US11352642B2 (en) 2015-01-09 2022-06-07 Etubics Corporation Methods and compositions for combination immunotherapy
CN104630145A (zh) * 2015-01-12 2015-05-20 杨世成 一种抗肿瘤t细胞、其制备方法和抗肿瘤药物
TWI772927B (zh) * 2015-03-31 2022-08-01 德商英麥提克生物技術股份有限公司 用於腎細胞癌(rcc)免疫治療的新型肽和肽組合物和支架
WO2016172249A1 (en) * 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy
CN104926944B (zh) * 2015-05-22 2018-04-13 北京康爱瑞浩生物科技股份有限公司空港分公司 多靶点复合抗原负载cd8+细胞毒性t淋巴细胞的制备方法及其用途
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
GB201511191D0 (en) * 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
CN108026154B (zh) 2015-07-01 2022-03-08 伊玛提克斯生物技术有限公司 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201512703D0 (en) 2015-07-20 2015-08-26 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
TWI765875B (zh) 2015-12-16 2022-06-01 美商磨石生物公司 新抗原辨識、製造及用途
CN105586312A (zh) * 2016-02-29 2016-05-18 时宏珍 Hla-a0201限制性抗muc-1抗原特异性ctl的制备方法
CA3038089A1 (en) * 2016-09-27 2018-04-05 Selecta Biosciences, Inc. Recombinant immunotoxins for use in the treatment of cancer
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
ES2963635T3 (es) * 2017-03-28 2024-04-01 Ohio State Innovation Foundation Vacunas de péptido PD1 humano y usos de las mismas
CN111548406A (zh) * 2017-04-10 2020-08-18 伊玛提克斯生物技术有限公司 用于癌症免疫治疗的肽及其肽组合物
MY197772A (en) * 2017-04-10 2023-07-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
BR112022001688A2 (pt) * 2019-07-30 2022-05-24 Univ Health Network Receptores de células t e métodos de uso dos mesmos
CN111363009B (zh) * 2020-03-18 2020-10-30 北京鼎成肽源生物技术有限公司 一种直肠癌靶标抗原及其刺激培养的ctl细胞及其应用
CN111617238B (zh) * 2020-06-02 2022-12-13 苏州药明康德新药开发有限公司 小鼠ct26结直肠癌治疗性肿瘤多肽疫苗制剂及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA725596A (en) 1960-08-26 1966-01-11 J. Wretlind Arvid Method of preparing intravenously injectable fat emulsions free from side reactions or complications
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US4803261A (en) * 1986-06-27 1989-02-07 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide
JPH02107189A (ja) * 1988-05-25 1990-04-19 City Of Hope 癌胎児抗原フラグメント
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU745863B2 (en) 1997-10-10 2002-04-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
US6756038B1 (en) * 1997-10-10 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
US6623923B1 (en) * 1998-12-23 2003-09-23 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
CA2384713A1 (en) * 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US20030017167A1 (en) * 2000-06-09 2003-01-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
EP1287029A2 (en) * 2000-06-09 2003-03-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20020102544A1 (en) * 2000-09-15 2002-08-01 David Mack Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
CA2427858A1 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
WO2002059609A2 (en) * 2000-12-08 2002-08-01 Eos Biotechnology, Inc. Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
JP2005518782A (ja) * 2001-09-17 2005-06-30 プロテイン デザイン ラブス， インコーポレイテッド ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法
WO2003084467A2 (en) * 2002-04-01 2003-10-16 Euro-Celtique S.A. Epitope constructs comprising antigen presenting cell targeting mechanisms
US20030211477A1 (en) * 2002-04-05 2003-11-13 Holmes Kathryn V. Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening
WO2004014867A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Matrix metalloproteinase inhibitors and methods for identification of lead compounds
WO2004061423A2 (en) * 2003-01-06 2004-07-22 Wyeth Compositions and methods for diagnosing and treating colon cancers
NZ543922A (en) * 2003-05-05 2008-05-30 Angeletti P Ist Richerche Bio Synthetic gene encoding human carcinoembryonic antigen and uses thereof
CN1727362B (zh) * 2004-07-30 2010-12-01 中国人民解放军第二军医大学 癌胚抗原阳性肿瘤治疗性疫苗的制备及应用
US20080254031A1 (en) * 2004-09-09 2008-10-16 Exonhit Therapeutics Sa Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis
SI1642905T1 (sl) * 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Imunogeni T-pomagalni epitop iz humanega tumornega antigena in imunoterapevtski postopki, ki uporabljajo navedeni epitop
ITRM20050064A1 (it) * 2005-02-16 2006-08-17 Univ Siena Peptide poliepitopico derivato dalla timidilato sintetasi avente attivita' immunologica e antitumorale e composizioni farmaceutiche relative.
ATE512160T1 (de) * 2005-04-26 2011-06-15 Immatics Biotechnologies Gmbh T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen
DE602005016112D1 (de) * 2005-09-05 2009-10-01 Immatics Biotechnologies Gmbh Tumorassoziierte Peptide, die HLA Klasse I oder II-Moleküle binden, und anti-Tumor Impfstoffe
DK1760088T3 (da) 2005-09-05 2008-06-09 Immatics Biotechnologies Gmbh Tumor associerede peptider, der bindes promiskuöst til human leuko-cyt-antigen (HLA) klasse II-molekyler
WO2008029271A2 (en) * 2006-02-27 2008-03-13 Gal Markel Ceacam based antibacterial agents
JP5352586B2 (ja) * 2007-07-27 2013-11-27 イマティクス バイオテクノロジーズ ゲーエムベーハー 腫瘍関連ペプチドおよび関連抗癌ワクチンの組成物
WO2009117656A2 (en) * 2008-03-21 2009-09-24 Vectorlogics,Inc. Capsid-incorporated antigen for novel adenovirus vaccine
HUE024541T2 (hu) * 2008-05-14 2016-01-28 Immatics Biotechnologies Gmbh Szurvivinbõl és neurocanból származó új és hatásos II-es osztályú MHC peptidek

Also Published As

Publication number Publication date
HUE032379T2 (en) 2017-09-28
CN103360466A (zh) 2013-10-23
CN101765434A (zh) 2010-06-30
CN101765434B (zh) 2014-12-17
EA201300322A1 (ru) 2013-10-30
UA103882C2 (uk) 2013-12-10
WO2009015841A1 (en) 2009-02-05
EA201000208A1 (ru) 2011-02-28
PT2567707T (pt) 2016-12-27
AU2008281013A2 (en) 2010-04-29
JP2010534627A (ja) 2010-11-11
ES2608583T3 (es) 2017-04-12
US20090148400A1 (en) 2009-06-11
PL2567707T3 (pl) 2017-03-31
EP2567707A3 (en) 2013-07-24
EP2178557A1 (en) 2010-04-28
AU2008281013B2 (en) 2012-06-28
CN103360466B (zh) 2016-08-03
DK2567707T3 (en) 2017-07-31
MX2010001088A (es) 2010-06-01
EA018457B1 (ru) 2013-08-30
EP2178557B1 (en) 2017-03-01
KR101167392B1 (ko) 2012-07-19
KR20100040875A (ko) 2010-04-21
HK1182923A1 (zh) 2013-12-13
JP5352586B2 (ja) 2013-11-27
LT2567707T (lt) 2017-01-10
JP2013165721A (ja) 2013-08-29
US7994276B2 (en) 2011-08-09
EP2567707B1 (en) 2016-10-05
AU2008281013A1 (en) 2009-02-05
NZ582823A (en) 2012-04-27
SI2567707T1 (sl) 2017-01-31
EP2567707A2 (en) 2013-03-13
CA2817054C (en) 2017-02-28
JP5746251B2 (ja) 2015-07-08
CA2817054A1 (en) 2009-02-05
CA2694771A1 (en) 2009-02-05
UA117216C2 (uk) 2018-07-10
EA023928B1 (ru) 2016-07-29

Similar Documents

Publication Publication Date Title
BRPI0814140A2 (pt) composição de peptídeos associados a tumor e vacina anticâncer relacionada
HK1172345A1 (en) Peptide vaccines for cancers expressing hig2 tumor-associated antigens hig2
EP2227556A4 (en) LUNG CANCER MARKERS AND THEIR USES
RU2448708C3 (ru) Противоопухолевое средство против рака щитовидной железы
HK1148688A1 (en) Composition and therapeutic anti-tumour vaccine
EP2006377A4 (en) NEW TUMORANT PEPTIDES
EP2794663A4 (en) PEPTIDE THERAPEUTIC CONJUGATES AND THEIR APPLICATIONS
BRPI0812765A2 (pt) Antígeno associado a cânceres de pulmão e linfomas
BRPI1014998A2 (pt) peptídio auxiliador de antígeno de câncer
GB0718167D0 (en) Cancer marker and therapeutic target
LTC2502996I2 (lt) Anti-FGF23 antikūnas ir jį apimanti farmacinė kompozicija
BRPI0812932A2 (pt) Composições e métodos de tratar câncer
HK1163735A1 (en) Tumor antigen peptide and use thereof
EP2176637A4 (en) MOUTH CANCER MARKERS AND THEIR DETECTION
HK1132911A1 (en) Cancer vaccine
BRPI0815772A2 (pt) Tratamento de câncer de pulmão
FI20075483A0 (fi) Uusi peptidi
DK2227486T3 (da) Peptidanaloger og konjugater dermed
GB0722773D0 (en) Cancer markers and uses thereof
GB0707417D0 (en) Cancer markers and uses thereof
GB0622142D0 (en) Aids & cancer cure + vaccine

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2472 DE 22-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.